COVID-19 mRNA Vaccine-induced Pneumonitis: A Case Report


Posted: 2021-10-28 19:00:00
Intern Med . 2021 Oct 26. doi: 10.2169/internalmedicine.8310-21. Online ahead of print. Affiliations Expand Affiliations 1 Department of Respiratory Medicine, Tatebayashi Kosei General Hospital, Japan. 2 Department of Pulmonology, International University of Health and Welfare, Japan. 3 Department of Dermatology, Tatebayashi Kosei General Hospital, Japan. 4 Department of Internal Medicine, Tatebayashi Kosei General Hospital, Japan. Item in Clipboard Shinichi Matsuzaki et al. Intern Med. 2021. Show details Display options Display options Format Intern Med . 2021 Oct 26. doi: 10.2169/internalmedicine.8310-21. Online ahead of print. Affiliations 1 Department of Respiratory Medicine, Tatebayashi Kosei General Hospital, Japan. 2 Department of Pulmonology, International University of Health and Welfare, Japan. 3 Department of Dermatology, Tatebayashi Kosei General Hospital, Japan. 4 Department of Internal Medicine, Tatebayashi Kosei General Hospital, Japan. Item in Clipboard CiteDisplay options Display options Format Abstract A 65-year-old man experienced cough and shortness of breath 3 days after receiving the first dose of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine. Chest X-ray revealed bilateral infiltrates, and the desaturation deteriorated rapidly. The symptoms and radiographic abnormalities rapidly improved after the initiation of corticosteroid therapy. Intradermal testing of the Pfizer-BioNTech COVID-19 vaccine showed a delayed positive reaction. Based on these findings, the patient was diagnosed with COVID-19 vaccine-induced pneumonitis. The timing of the onset of pneumonitis after vaccination and the results of intradermal testing suggest that Type IV hypersensitivity against COVID-19 vaccine may have been responsible for this clinical condition. Keywords: COVID-19; intradermal testing; mRNA vaccine; vaccine-induced pneumonitis.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
1月 29, 2021 バイオアソシエイツ

臍帯間葉系幹細胞による重度COVID-19治療で画期的な成果が報告された

マイアミ大学ミラー医学部の研究者らは、臍帯由来の間葉系幹細胞の注入によって最も重症の COVID-19 患者の死亡リスクを安全に減らし、回復までの時間を短縮することを示す、ユニークで画期的なランダム化比較試験を主導した。 STEM CELLS Translational Medicineで2021年1月5日に掲載されたこのオープンアクセス論文は「COVID-19急性呼吸窮迫症候群の臍帯間葉系幹細胞:二重盲検、フェーズ1 / 2a、ランダム化比較試験(Umbilical Cord Mesenchymal Stem…

ゲスト 572人 と メンバー 6人 がオンラインです